Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Pharmacists Directed Medication Reconciliation on Reducing Medication Discrepancies in a Surgery Ward

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03928106
Recruitment Status : Completed
First Posted : April 25, 2019
Last Update Posted : April 25, 2019
Sponsor:
Information provided by (Responsible Party):
Khawla Abu Hammour, University of Jordan

Brief Summary:

Several previous studies have investigated the impact of a pharmacists-provided medication reconciliation service on medication discrepancies in the hospital settings Results showed that pharmacists were able to identify a range of 1.5-2.3 unintentional discrepancies per patient, leading to a significant reduction of 40-75% of the total identified medication discrepancies. No previous study has investigated the outcomes of involving the clinical pharmacist in a medication reconciliation service in in Jordan.

Acknowledging the importance of evaluating the value of medication reconciliation services in the different healthcare settings, this study is designed with the aim to evaluate the effect of pharmacists directed services (reconciliation plus counseling) on reducing medication discrepancies and improving patient's outcomes at discharge.


Condition or disease Intervention/treatment Phase
Safety Issues Other: pharmacists' recommendation Not Applicable

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 123 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Health Services Research
Official Title: Impact of Pharmacists Directed Medication Reconciliation on Reducing Medication Discrepancies in a Surgery Ward in an Educational Hospital in Jordan
Actual Study Start Date : April 1, 2017
Actual Primary Completion Date : July 30, 2017
Actual Study Completion Date : July 30, 2017

Arm Intervention/treatment
intervention
pharmacist responsible for enrollment will administer the following interventions: identifying the medication discrepancies make the recommendations to correct these discrepancies contact the physician to resolve these discrepancies
Other: pharmacists' recommendation
For patients in the intervention group, upon identification of drug discrepancies, pharmacist responsible for enrollment will be intervened by contacting the responsible clinician using a structured written consult form. The number of accepted recommendations by the clinicians will be documented and recorded. When the researcher suggests resolving an identified discrepancy and the responsible clinicians accept the suggestion will be called an accepted recommendation (just an acceptance without any correction), if the accepted suggestion is implemented then this will be called implemented recommendation.

control
pharmacists will identify medication discrepancies no recommendation will be written by pharmacists to solve these discrepancies
Other: pharmacists' recommendation
For patients in the intervention group, upon identification of drug discrepancies, pharmacist responsible for enrollment will be intervened by contacting the responsible clinician using a structured written consult form. The number of accepted recommendations by the clinicians will be documented and recorded. When the researcher suggests resolving an identified discrepancy and the responsible clinicians accept the suggestion will be called an accepted recommendation (just an acceptance without any correction), if the accepted suggestion is implemented then this will be called implemented recommendation.




Primary Outcome Measures :
  1. The number of accepted recommendations by the clinicians will be documented and recorded, an accepted recommendation, and implemented recommendation [ Time Frame: From date of randomization until the date of first documented progression, assessed through study completion an average of 3 months ]
    The number of accepted recommendations by the clinicians will be documented and recorded, an accepted recommendation, implemented recommendation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age ≥18 years
  • using at least 4 regular pre-admission medications
  • more than 48 hours expected length of stay in the hospital
  • speaks Arabic
  • has no cognitive deficiency
  • not involved in any other clinical trial

Exclusion Criteria:

  • if they were in isolation
  • discharged within 24 hours of admission
  • discharged against medical advice
  • unable or unwilling to provide written informed consent
  • unable to provide a personal phone number
  • patients who were enrolled were ineligible for re-inclusion in the study
  • if they were admitted to JUH a second time during the study period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03928106


Locations
Layout table for location information
Jordan
Jordan University Hospital
Amman, Jordan, 00962
Sponsors and Collaborators
University of Jordan

Additional Information:
Layout table for additonal information
Responsible Party: Khawla Abu Hammour, Dr Associate professor (Principal Investigator), University of Jordan
ClinicalTrials.gov Identifier: NCT03928106     History of Changes
Other Study ID Numbers: 65/2017
First Posted: April 25, 2019    Key Record Dates
Last Update Posted: April 25, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Khawla Abu Hammour, University of Jordan:
Medication Reconciliation